BioSpace News Archive

Primary efficacy endpoint met with 87.7% response rate at one year; women experienced, on average, an 89.9% reduction in menstrual blood loss Bone mineral density maintained through one year, with no new safety signals Data further strengthen the New Drug Application (NDA) expected to be submitted in April 2020 BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health a

Awards for achievement in the contact lens field were presented recently to three team members of Innovega, a company engaged in developing stylish, lightweight, wearable display technology with a panoramic field of view for virtual and augmented reality

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at Noble Capital Markets’ 16th Annual Investor Conference on Monday, February 17, 2020 at 4:00 PM ET . The c

- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter of calendar year 2020 - 87.7% one-year response rate in LIBERTY open-label extension study supports submission of NDA for relugolix combination tablet for women with heavy menstrual bleeding associated with uterine fibroids in April 2020 - Enrollment completed in Phase 3 SPIRIT 2 and SPIRIT 1 studies in women w

Feb. 10, 2020 13:30 UTC -- If Approved, Kite Could be First Company with Multiple Commercialized CAR T Therapies -- SANTA MONICA, Calif.--( BUSINESS WIRE )-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with r

Feb. 10, 2020 13:30 UTC Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer – Company also provides update on timeline for pivotal ZEPHYR study – ANN ARBOR, Mich.--( BUSINESS WIRE )-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Christophe Arbet-Engels, MD, PhD, has joined the company as Chief Medi

Gento (formerly Nursing Without Walls) a startup that provides on-demand staffing and care delivery management to home health agencies and skilled nursing facilities through their platform and mobile app, announces today a $5M Series A funding by Jeff Anderson at Palisades Growth Capital

Healogics® Inc., the nation’s leading provider of advanced wound care services, proudly announces the newest release of WoundSuite® Navigator, the physician relationship management mobile app.

“We can look back on a very strong quarter in which Group sales grew by a significant 22 percent adjusted for currency, driven in particular by Integrated Solutions, whose sales adjusted for currency rose by a remarkable 45 percent.

MIRAMAR, Fla., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the team from NuGenerex Immuno-Oncology will hold an investor conference call on Thursday February 13, 2020 at 11:00 AM Eastern time. Agenda 2019-nCOV coronavirus initiatives 5/2 dividends in Generex and NuGenerex Immuno-Oncology ALTuCELL Closing S1 funding update Nasdaq listing update